...
首页> 外文期刊>Diabetes therapy >Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.
【24h】

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.

机译:威格列汀在日本2型糖尿病患者中添加或不添加二甲双胍的疗效和安全性:一项为期12周的双盲随机研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Treatment with vildagliptin 50?mg bid as add-on to insulin with or without metformin resulted in statistically significant reductions in HbA1c in Japanese patients with T2DM. Overall, vildagliptin was well tolerated with a safety profile similar to that of placebo in this patient population. ClinicalTrials.gov Identifier, NCT02002221 FUNDING: Novartis Pharma K.K.
机译:在日本患有T2DM的患者中,使用维达列汀50 mg bid作为胰岛素的加用药物(有或没有二甲双胍)可导致HbA1c的统计学下降。总体而言,该患者人群对维达列汀的耐受性良好,其安全性与安慰剂相似。 ClinicalTrials.gov标识符,NCT02002221资金:Novartis Pharma K.K.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号